Global	B:C0035171
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
Chronic	O
Obstructive	I:C0024117
Lung	I:C0024117
Disease	I:C0024117
2017	O
Report	O
.	O

Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	B:C1704656
,	O
Management	O
,	O
and	O
Prevention	O
of	O
Chronic	O
Obstructive	I:C0024117
Lung	I:C0024117
Disease	I:C0024117
2017	O
Report	O
.	O

Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	B:C0376636
,	O
and	O
Prevention	O
of	O
Chronic	O
Obstructive	I:C0024117
Lung	I:C0024117
Disease	I:C0024117
2017	O
Report	O
.	O

Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	B:C1706420
of	O
Chronic	O
Obstructive	I:C0024117
Lung	I:C0024117
Disease	I:C0024117
2017	O
Report	O
.	O

Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
Chronic	B:C0024117
Obstructive	I:C0024117
Lung	I:C0024117
Disease	I:C0024117
2017	O
Report	O
.	O

GOLD	B:C0282574
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	B:C0282574
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	B:C0035171
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	B:C1704656
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	B:C0376636
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	B:C1706420
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	B:C0024117
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	B:C0282574
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	B:C0282574
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	B:C0684224
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	B:C1527075
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

GOLD	O
Executive	I:C0282574
Summary	I:C0282574
This	O
Executive	O
Summary	I:C0282574
of	O
the	O
Global	O
Strategy	I:C0035171
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	I:C0282574
for	I:C0282574
Chronic	I:C0282574
Obstructive	I:C0282574
Lung	I:C0282574
Disease	I:C0282574
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	B:C1301746
.	O

The	O
most	O
significant	O
changes	O
include	O
:	O
(	O
1	O
)	O
the	O
assessment	B:C0220825
of	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
has	O
been	O
refined	O
to	O
separate	O
the	O
spirometric	O
assessment	I:C0037981
from	O
symptom	O
evaluation	I:C3494438
.	O

The	O
most	O
significant	O
changes	O
include	O
:	O
(	O
1	O
)	O
the	O
assessment	O
of	O
chronic	B:C0024117
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
has	O
been	O
refined	O
to	O
separate	O
the	O
spirometric	O
assessment	I:C0037981
from	O
symptom	O
evaluation	I:C3494438
.	O

The	O
most	O
significant	O
changes	O
include	O
:	O
(	O
1	O
)	O
the	O
assessment	O
of	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
has	O
been	O
refined	O
to	O
separate	O
the	O
spirometric	B:C0037981
assessment	I:C0037981
from	O
symptom	O
evaluation	I:C3494438
.	O

The	O
most	O
significant	O
changes	O
include	O
:	O
(	O
1	O
)	O
the	O
assessment	O
of	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
has	O
been	O
refined	O
to	O
separate	O
the	O
spirometric	O
assessment	I:C0037981
from	O
symptom	B:C3494438
evaluation	I:C3494438
.	O

ABCD	B:C1257890
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	B:C0332119
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	B:C4086268
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	B:C1257890
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	B:C0035171
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	B:C0087111
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	B:C3651014
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	B:C0087111
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	B:C0087111
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	B:C0220825
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	B:C1519193
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	B:C1275743
conditions	I:C1275743
in	O
managing	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

ABCD	O
groups	I:C1257890
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	I:C0332119
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	I:C1275743
in	O
managing	O
chronic	B:C0024117
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
is	O
reviewed	O
.	O

